• <code id="kgams"><tr id="kgams"></tr></code>
    <abbr id="kgams"></abbr>
  • <abbr id="kgams"></abbr>
    Home
    Who We Are
    What We Do
    Corporate Responsibility
    News
    Careers
    Investors
    Patients and HCPS
    Contact us
    Careers | Investors | Patients and HCPS | Contact us
    Careers Investors Patients and HCPS Contact us
    Home / Company News / Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
    Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
    Date:2024-11-13
    • After two weeks of treatment, GZR18 tablets resulted in an average weight reduction of up to 4.16%, with continued weight loss observed even after discontinuation.

    • The pharmacokinetic profile supports a once-daily oral dosing regimen for GZR18 tablets.

    • The safety and tolerability of GZR18 tablets align with the known safety characteristics of GLP-1 receptor agonists, with no unexpected safety signals during the study.

     

    Beijing, China — Gan & Lee Pharmaceuticals (Gan & Lee, Shanghai Stock Exchange: 603087) announced the positive topline results of a Phase 1 clinical trial its oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) GZR18 tablets in healthy participants in China.

     

    Statement:

    1. GZR18 tablet is an ivestigational drug and has not yet been approved in China.

    2. Gan & Lee Pharmaceuticals does not recommend the use of any unapproved drugs/indications.

     

    The Phase 1 clinical trial (CTR20240663) was a randomized, open-label, first-in-human study involving 92 participants, designed to assess the bioavailability, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of GZR18 tablets in healthy adult participants. The study also evaluated the effect of meal timing on the drug's PK, PD, safety, and tolerability.

     

    In this study, GZR18 tablets were safe and well-tolerated, with the most common adverse events being gastrointestinal reactions, consistent with the established safety profile of GLP-1 based therapies. PK data indicated favorable absorption, supporting a once-daily oral regimen. Both single and multiple doses showed a dose-response relationship in terms of PK and PD parameters. Participants treated with the target dose of 60 mg daily for two weeks exhibited an average weight reduction of 4.16% from baseline. Furthermore, a week after stopping treatment, subjects continued to lose weight 0.51%, reaching an average total reduction of 4.67% compared to baseline. At 21 days after discontinuation, neither the participants' body weight nor BMI had returned to baseline values.

     

    About GZR18 Tablets

    GZR18 tablet is an investigational, once-daily oral GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals. It utilizes a small molecule absorption enhancer, SNAC (N-[8-(2-hydroxybenzoyl)amino] caprylate), to facilitate drug absorption in the stomach by resisting pepsin degradation, thus prolonging the drug's half-life and enhancing its bioavailability. GZR18 tablets are currently in global Phase 1 clinical development.

     

    Forward-looking statements

    Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


    About Gan & Lee

    Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin?), fast-acting lispro injection (Prandilin?), fast-acting aspart injection (Rapilin?), mixed protamine zinc lispro injection (25R) (Prandilin?25), aspart 30 injection (Rapilin?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin?30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine?).

     

    In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine?) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

     

    In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.


    Copyright ? 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP備10213074號-1 | 京公網安備 11011202003900號
    Our websites

    Subscribe

    I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.
    主站蜘蛛池模板: 亚洲欧洲国产精品久久| 国产gav成人免费播放视频| 久久综合国产乱子伦精品免费| 免费观看无遮挡www的视频| 案件小说h阿龟h全文阅读| 国产成人综合色视频精品| 久久中文字幕无码专区| 精品国产一区二区三区免费 | 久久午夜无码鲁丝片直播午夜精品| 野花日本免费观看高清电影8| 成年女人永久免费观看片| 国产精品亚洲综合久久| 久久精品天天中文字幕人妻| 亚洲国产香蕉视频欧美| 日本欧美韩国专区| 国产又大又长又粗又硬的免费视频| 久久亚洲色一区二区三区| 精品国产v无码大片在线观看| 在线看免费毛片| 亚洲国产成人一区二区精品区| 阿娇与冠希13分钟视频未删减 | 国产一区二区三区久久精品| yellow版字幕网| 欧美人与zoxxxx另类| 国产精品久久久久影院| 久久亚洲AV无码精品色午夜麻豆| 精品伊人久久久大香线蕉欧美| 国产精品视频李雅| 久久亚洲伊人中字综合精品| 真正国产乱子伦高清对白| 国产精品一区二区在线观看| 丰满黄蓉跪趴高撅肥臀| 色噜噜人体337p人体| 在线观看的黄网| 久久精品国产96精品亚洲| 精品91自产拍在线| 国产特级毛片aaaaaaa高清| 中文字幕+乱码+中文乱码www| 欧美激情高清整在线| 国产丝袜无码一区二区三区视频| 久久国产精品成人片免费|